Brief: Nicox Says NCX 470 Dolomites Phase 2 Results Published In Journal Of Glaucoma

Nicox SA

11/04/2022 06:36

April 11 (Reuters) - Nicox SA  NCOX.PA :
    * NCX 470 DOLOMITES PHASE 2 RESULTS PUBLISHED IN JOURNAL OF
GLAUCOMA
    * NCX 470 WAS SAFE AND WELL-TOLERATED WITH NO DRUG-RELATED
SERIOUS
ADVERSE EVENTS AND NO EVIDENCE OF TREATMENT-RELATED SYSTEMIC
SIDE EFFECTS
    * NCX 470 IS CURRENTLY IN TWO PHASE 3 CLINICAL TRIALS

Source text for Eikon:  ID:nGNE7MyMk5 
Further company coverage:  NCOX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))